PMGC subsidiary NorthStrive files U.S. patent for EL-22 muscle preservation in humans

PMGC Holdings Inc.

New U.S. patent application (No. 19/655,160) covers EL-22 as a formulated pharmaceutical product for muscle loss.
EL-22 uses myostatin-engineered probiotic technology targeting sarcopenia, disuse atrophy, and neurological disorders.
The patent includes dosing regimens and formulations; potential use with GLP-1 receptor agonist weight loss treatments.
This filing expands NorthStrive's IP strategy for muscle health therapeutics across pharmaceutical and adjacent markets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.